Halozyme rises ahead of Q1 results as ENHANZE royalty outlook stays in focus
Halozyme Therapeutics shares are higher Tuesday ahead of its first-quarter 2026 earnings release later today, with investors positioning for updates on ENHANZE royalty momentum. Optimism is also tied to expanding partner activity, including Roche adding a new ENHANZE target nomination earlier this year.
1. What’s moving HALO today
Halozyme Therapeutics (HALO) is up about 3% in Tuesday trading as investors position ahead of the company’s first-quarter 2026 financial and operating results expected after the market close. With no single new headline dominating the tape, the move looks driven by event-driven buying into the earnings catalyst and expectations that the company’s royalty-heavy model can continue to deliver strong year-over-year growth.
2. What the market is watching
The key focus is the trajectory of ENHANZE-enabled partner products and the resulting royalty stream, which has become the company’s primary earnings engine. Investors are also monitoring any incremental signs of partner expansion—Halozyme previously disclosed Roche added a new ENHANZE target nomination—because additional programs can lengthen and deepen the long-duration royalty profile that underpins Halozyme’s valuation.
3. Why sentiment has support into the print
Halozyme has been guiding to strong 2026 performance, including a step-up in total revenue and royalties, and the stock has tended to react strongly to guidance clarity. The broader backdrop also includes recent regulatory momentum for ENHANZE-related products such as the FDA approval of a subcutaneous formulation combining amivantamab with hyaluronidase (Rybrevant Faspro), a type of milestone that can reinforce confidence in the commercial durability of Halozyme’s subcutaneous delivery ecosystem.